Drug Trial Radar · NCT07636811
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Aug 17, 2026
Primary completion
May 18, 2030
Study completion Jul 30, 2031
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Jun 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effect of mivelsiran in adult participants with early-stage DS-AD and to characterize the safety, tolerability, and pharmacodynamics (PD) of mivelsiran. The study will be conducted over 2 periods: a 24-month double-blind period and an optional 12-month open-label treatment extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 39 months.
Conditions
- Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Interventions
MivelsiranDrug
Mivelsiran will be administered intrathecally
PlaceboDrug
Placebo will be administered intrathecally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double-Blind Period: Change from baseline in brain amyloid burden measured in centiloids (CLs)Time frame: Up to 24 months
Locations
20 sites in 3 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Maitland, Florida · Recruiting
Clinical Trial Site
Naples, Florida · Recruiting
Clinical Trial Site
Fishers, Indiana · Not yet recruiting
Clinical Trial Site
Indianapolis, Indiana · Recruiting
Clinical Trial Site
Kansas City, Kansas · Recruiting
Clinical Trial Site
St Louis, Missouri · Recruiting
Clinical Trial Site
Cincinnati, Ohio · Recruiting
Clinical Trial Site
Cincinnati, Ohio · Not yet recruiting
Clinical Trial Site
Nashville, Tennessee · Not yet recruiting
Clinical Trial Site
Nashville, Tennessee · Recruiting
Clinical Trial Site
Beaumont, Texas · Recruiting
Clinical Trial Site
Madison, Wisconsin · Not yet recruiting
Clinical Trial Site
Madison, Wisconsin · Recruiting
Clinical Trial Site
Barcelona, Spain · Recruiting
Clinical Trial Site
Dos Hermanas, Spain · Recruiting
Clinical Trial Site
Madrid, Spain · Recruiting
Clinical Trial Site
Pamplona, Spain · Recruiting
Clinical Trial Site
Seville, Spain · Recruiting
Clinical Trial Site
Valencia, Spain · Recruiting
Clinical Trial Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.